The U.S. Supreme Court ruled in favor of health insurers seeking $12 billion from the federal government under a program set up by the Obamacare law aimed at encouraging them to offer medical coverage to previously uninsured Americans.
Civica Rx and 18 independent Blue Cross and Blue Shield (BCBS) companies formed a new subsidiary dedicated to lowering the cost of select generic drugs.
Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract slowed the rate of medical spending growth by up to 12 percent while improving patient care over the course of eight years, according to a Harvard Medical School study published in the New England Journal of Medicine.
As concerns over the price of prescription medicine continue to make headlines as the country barrels toward another election, a new study from the Scripps Research bolsters an argument touted by the pharmaceutical industry over the rebate system.
Participating in the Blue Cross Blue Shield Alliance for Health Research, the study comes from Yale’s School of Public Health and School of Medicine NEW HAVEN, Conn., March 22, 2019 /PRNewswire/ –State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say […]
Amgen Inc.’s push to get patients on its new $575 a month migraine drug before competition emerges in September 2018 is facing barriers from insurers.
Amazon.com Inc., Berkshire Hathaway and JPMorgan Chase & Co. will form a healthcare company aimed at cutting costs for their U.S. employees, they said on Tuesday, sending shares in the broad healthcare sector sharply lower.
President Donald Trump’s 90 percent cut to Obamacare advertising has U.S. health insurers in many states digging deeper into their pockets to get the word out about 2018 enrollment.